PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis

Company Overview

PharmaCyte Biotech, Inc. is a biotechnology company focused on developing treatments for cancer, with particular emphasis on pancreatic cancer. The company’s platform is based on its “Cell-in-a-Box” technology, which uses encapsulated, genetically engineered human cells to produce an enzyme that can convert certain chemotherapy agents into their active forms near tumor tissue.

PharmaCyte’s lead therapeutic approach combines the encapsulated cells with ifosfamide, a chemotherapy drug. The strategy is intended to increase the concentration of active chemotherapy in and around a tumor while limiting exposure to healthy tissue. The company has primarily pursued this approach as a potential treatment for locally advanced pancreatic cancer and has conducted clinical-development activities related to that indication.

The company was formerly known as Nuvilex, Inc. and adopted the PharmaCyte Biotech name as it shifted its focus toward oncology and its Cell-in-a-Box platform. Its development programs have been directed primarily toward the U.S. market, although the company has worked with international research, manufacturing and clinical-development partners. PharmaCyte Biotech’s business remains centered on biotechnology research and the development of potential cancer therapies rather than the sale of approved commercial products.

Key Stats

• Today's Range: $0.42 to $0.45
• 50-Day Range: $0.42 to $0.62
• 52-Week Range: $5.56 to $55.50
• Volume: 110,848 shs
• Average Volume: 8,831 shs
• Market Capitalization: $700.15 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PMCBD
• CIK: N/A
• Web: www.pharmacyte.com
• Phone: (917) 595-2850
• Fax: N/A
• Employees: N/A
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.83 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.09%
• Return on Assets: -43.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.90
• Quick Ratio: 4.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,671,000
• Free Float: N/A
• Market Cap: $700.15 thousand
• Optionable: Not Optionable
• Beta: 0.27